Skip to content
WeighLab
Menu
Ranked #429 · Grade C

Willow review

Willow is a direct-to-consumer telehealth provider offering compounded semaglutide and tirzepatide in both injectable and oral-tablet form at identical prices per format.

Visit Willow Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Compounded only

Pricing verified August 2026

The Index scorecard

Willow scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month45/100
Price Transparency54/100
Nationwide Access24/100
Formulation Options51/100
Clinical Oversight79/100
Contract Flexibility55/100

Where the value is

  • Oral tablet formulations of both semaglutide and tirzepatide, priced identically to the injectable versions ($299/mo and $399/mo respectively) — a genuine format choice most compounded-drug competitors don't offer
  • Month-to-month billing with no prepay or annual term required to get the advertised rate
  • Named physician team publicly listed, including Chief Medical Officer Dr. Michael Green, MD, plus 11+ other credentialed MDs/DOs
  • FAQ explicitly states no hidden fees beyond the monthly price (aside from an extra 'platform fee' only if using an outside pharmacy)
  • Free 2-day shipping and HSA/FSA eligibility

The tradeoffs

  • Only 34 states served — notably narrower than WeightlessRx's 49-state footprint; residents of the other 16 states plus DC are excluded
  • Site states medication cost 'varies by dosage and prescription' but never discloses what a higher maintenance dose actually costs beyond the $299/$399 starting figures
  • Compounding pharmacy name and state are not disclosed anywhere on the site
  • No LegitScript certification badge or mention found on any page checked
  • Site's own safety disclosure confirms these are compounded, not FDA-approved formulations — explicitly 'not substitutes for FDA-approved medications such as MOUNJARO®, ZEPBOUND™, Wegovy®, or Ozempic®'

The bottom line

Best for: Cost-first shoppers who want an oral-tablet GLP-1 option at the same price as the injectable, with no annual commitment. Willow is a direct-to-consumer telehealth provider offering compounded semaglutide and tirzepatide in both injectable and oral-tablet form at identical prices per format.

Ranked #429 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Willow.

The 24 programs nearest this one

Pricing, states and verification reflect Willow's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Willow's site. Not medical advice; see our disclosure.

← Back to the value leaderboard